Caricamento...
Does levosimendan act as a Ca(2+) sensitizer or PDE3 inhibitor?: Commentary on Orstavik et al., Br J Pharmacol 171: 5169–5181
This article is a Commentary on Orstavik O, Ata SH, Riise J, Dahl CP, Andersen GO, Levy FO, Skomedal T, Osnes J-B, and Qvigstad E (2014). PDE3-inhibition by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br J Pharmacol 171: 5169–5181. doi: 10.1111/bph.12647
Salvato in:
| Pubblicato in: | Br J Pharmacol |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Ltd
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4562519/ https://ncbi.nlm.nih.gov/pubmed/24547894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12649 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|